These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 32732092)

  • 21. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
    Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
    Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.
    Ooki A; Osumi H; Yoshino K; Yamaguchi K
    Gastric Cancer; 2024 Sep; 27(5):907-931. PubMed ID: 38922524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
    Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
    World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microsatellite instability: A 2024 update.
    Yamamoto H; Watanabe Y; Arai H; Umemoto K; Tateishi K; Sunakawa Y
    Cancer Sci; 2024 Jun; 115(6):1738-1748. PubMed ID: 38528657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T; Tougeron D; Piessen G; de la Fouchardière C; Louvet C; Adenis A; Jary M; Tournigand C; Aparicio T; Desrame J; Lièvre A; Garcia-Larnicol ML; Pudlarz T; Cohen R; Memmi S; Vernerey D; Henriques J; Lefevre JH; Svrcek M
    J Clin Oncol; 2023 Jan; 41(2):255-265. PubMed ID: 35969830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
    Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
    Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ; Yuan P; Zhai JN; Yao YF; Tan LX; Li ZW; Zhang XY; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):684-693. PubMed ID: 39004983
    [No Abstract]   [Full Text] [Related]  

  • 31. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
    Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
    JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
    Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
    Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.
    Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y
    Front Immunol; 2021; 12():784336. PubMed ID: 34975873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
    JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
    Yu JH; Xiao BY; Li DD; Jiang W; Ding Y; Wu XJ; Zhang RX; Lin JZ; Wang W; Han K; Kong LH; Zhang XK; Chen BY; Mei WJ; Pan ZZ; Tang JH; Zhang XS; Ding PR
    Lancet Oncol; 2024 Jul; 25(7):843-852. PubMed ID: 38852601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
    Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.